Laura T. Bortolin
Research Subjects
Laura T. Bortolin has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Anthony D. Couvillon
Mercy BioAnalytics Inc.; Waltham, MA USA
2 shared publications - Daniel P. Salem
Mercy BioAnalytics, Inc., Waltham, USA
2 shared publications - Dawn R. Mattoon
Mercy BioAnalytics Inc.; Waltham, MA USA
2 shared publications - Emily S. Winn-Deen
Mercy BioAnalytics Inc.; Waltham, MA USA
2 shared publications - Eric K. Huang
Mercy BioAnalytics Inc.; Waltham, MA USA; Current address: Massachusetts Bay Transportation Authority; Boston, MA USA
2 shared publications - Ibukunoluwapo O. Zabroski
Mercy BioAnalytics Inc.; Waltham, MA USA
2 shared publications
Latest Publications
- Open Access
- 24 September 2024
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 26 (12) , 1109-1128
Colocalization of Cancer-Associated Biomarkers on Single Extracellular Vesicles for Early Detection of Cancer
- 24 September 2024
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 26 (12) , 1109-1128
Open AccessColocalization of Cancer-Associated Biomarkers on Single Extracellular Vesicles for Early Detection of Cancer
- Open Access
Colocalization of Cancer Associated Biomarkers on Single Extracellular Vesicles for Early Cancer Detection
Detection of cancer early, when it is most treatable, remains a significant challenge due to the lack of diagnostic methods sufficiently sensitive to detect nascent tumors. Early-stage tumors are small relative to their tissue of origin, heterogeneous, and infrequently manifest in clinical symptoms. Detection of their presence is made more difficult by a lack of abundant tumor-specific indicators (i.e., protein biomarkers, circulating tumor DNA, etc.) that would enable detection using a non-invasive diagnostic assay. In addition, many benign conditions manifest in a similar manner, thus discriminating an early-stage cancerous lesion from a benign tumor can present additional challenges and result in unnecessary medical procedures. To overcome these obstacles, we have developed a liquid biopsy assay that interrogates circulating extracellular vesicles (EVs) to detect tumor-specific biomarkers colocalized on the surface of individual EVs. Extracellular vesicles from all cell types, including early-stage tumors, are known to be abundant in blood, are remarkably stable, and serve as a biopsy of their cell of origin. The detection of a colocalized combination of cancer associated biomarkers that provide tumor specificity on the surface of extracellular vesicles enables the discrimination of early- and late-stage cancer from non-malignant conditions.
Open AccessColocalization of Cancer Associated Biomarkers on Single Extracellular Vesicles for Early Cancer Detection
Detection of cancer early, when it is most treatable, remains a significant challenge due to the lack of diagnostic methods sufficiently sensitive to detect nascent tumors. Early-stage tumors are small relative to their tissue of origin, heterogeneous, and infrequently manifest in clinical symptoms. Detection of their presence is made more difficult by a lack of abundant tumor-specific indicators (i.e., protein biomarkers, circulating tumor DNA, etc.) that would enable detection using a non-invasive diagnostic assay. In addition, many benign conditions manifest in a similar manner, thus discriminating an early-stage cancerous lesion from a benign tumor can present additional challenges and result in unnecessary medical procedures. To overcome these obstacles, we have developed a liquid biopsy assay that interrogates circulating extracellular vesicles (EVs) to detect tumor-specific biomarkers colocalized on the surface of individual EVs. Extracellular vesicles from all cell types, including early-stage tumors, are known to be abundant in blood, are remarkably stable, and serve as a biopsy of their cell of origin. The detection of a colocalized combination of cancer associated biomarkers that provide tumor specificity on the surface of extracellular vesicles enables the discrimination of early- and late-stage cancer from non-malignant conditions.